key: cord-0776618-uvkf1min authors: Kamegai, Kohei; Iwamoto, Noriko; Togano, Tomiteru; Maeda, Kenji; Takamatsu, Yuki; Miyazato, Yusuke; Ishikane, Masahiro; Mizokami, Masashi; Sugiyama, Masaya; Iida, Shun; Miyamoto, Sho; Suzuki, Tadaki; Ohmagari, Norio title: A Fatal Breakthrough Coronavirus Disease 2019 Case Following Bendamustine–Rituximab Therapy date: 2022-04-30 journal: Int J Infect Dis DOI: 10.1016/j.ijid.2022.04.058 sha: 70465f61a7faaf5959f70e2edc7025dc65a078c2 doc_id: 776618 cord_uid: uvkf1min Although messenger ribonucleic acid vaccines are substantially effective toward severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, patients with hematological malignancies are still prone to the virus. Herein, we report a fatal case of breakthrough SARS-CoV-2 delta variant infection in a patient with mucosa-associated lymphoid tissue lymphoma with remission by bendamustine–rituximab (BR) therapy completed a year ago. The serological study revealed impaired responsiveness toward vaccines and prolonged high viral load after infection. BR therapy seemingly induced an immune escape. Prevention and treatment strategies for such vulnerable patients should be clarified immediately. Patients with hematological malignancy are at high risk of developing critical coronavirus disease 2019 (COVID-19) because of immunologic unresponsiveness toward severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines (García-Suárez et al., 2020; Greenberger et al., 2021) . Establishing strategies for treating such patients has not yet been addressed. We report a fatal, critical case of COVID-19 following two messenger ribonucleic acid (mRNA) vaccine doses which has been validated by detailed serological, virological, and cytokine kinetic studies. Herein, we present an Asian man in his 70s who had received six courses of bendamustinerituximab (BR) therapy (rituximab 375 mg/m 2 [day 1], bendamustine 90 mg/m 2 [days 1 and 2]) for stage-Ⅲ mucosa-associated lymphoid tissue (MALT) lymphoma. Chemotherapy was completed 1 year before hospital admission. Positron emission tomography/computed tomography (PET/CT) performed 8 months before the admission revealed a complete metabolic response of the lymphoma lesions, and there was no evidence of relapse since then. His total lymphocyte count and total serum IgG level were within normal limits during outpatient visits. His clinical course is shown in Supplementary Figure. The patient developed a fever at home 11 days after his second dose of the mRNA vaccine BNT162b2 (disease day 0). On disease day 10, he was transferred by ambulance from home to our hospital owing to his worsened status. On arrival, his oxygen saturation was 56% while he was breathing ambient air. We started remdesivir, 2 mg/kg per day methylprednisolone, and a single dose of 8 mg/kg tocilizumab. He required a non-invasive, positive-pressure ventilator for hypoxemia. On disease day 19, his oxygen level abruptly dropped, and intubation was needed. On disease day 26, soon after extubation, he developed pneumothorax and acute respiratory distress syndrome. He died on disease day 31. Before admission, even after receiving the BR regimen, his total serum IgG level and total lymphocyte counts were approximately within the normal limits. During his admission due to severe COVID-19, his lymphocyte counts considerably dropped to less than 200/mm 3 . The serum SARS-CoV-2-neutralizing activity was determined in vitro with wild-type SARS-CoV-2 (Phylogenetic Assignment of Named Global Outbreak (PANGO) lineage B) and transmembrane protease, serine 2 (TMPRSS2)-overexpressing VeroE6 cells as previously described (Maeda et al., 2021.) . The activity on admission (disease day 10) was under the detection limit (50% neutralizing titer [NT 50 ] < 20-fold) even 3 weeks after the second dose of BNT162b2. The activity increased by disease day 19 and slightly decreased by disease day 27 with NT 50 values of 360-fold and 170-fold, respectively, compared with the NT 50 value of 850-fold of the best 2% of 340 neutralizing-activity-determined convalescent plasma samples (Takamatsu et al., 2021) . Table) . Our patient succumbed to a fatal course after receiving two doses of an mRNA SARS-CoV-2 vaccine. The blood test results described above indicated that the patient failed to acquire sufficient anti-SARS-CoV-2-neutralizing antibodies and immunological responses even after 2 doses of BNT-162b2 vaccination with undetectable serum neutralizing activity and anti-SARS-CoV-2-Spike IgG (Table) . An increase in SARS-CoV-2-neutralizing activity was observed 19 days after the infection as a booster effect. We attribute this fatal case to four causes: (I) impaired responsiveness toward SARS-CoV-2 vaccine, (II) prolonged high SARS-CoV-2 viral load, (III) difficulties in controlling T-cell immunodeficiency and cytokine storm, and (Ⅳ)the possibility of bacterial superinfection. The patient had received bendamustine, a purine analog that dramatically reduces the function of CD4+ T-cell (Gafter-Gvili et al., 2016) . We suggest lymphoma itself is responsible for (I) (Agha et al., 2021) , whereas bendamustine is responsible for (II) and (III) and rituximab is responsible for (I), (II), and (III). The four causes are discussed below. Firstly, in this patient, even at 3 weeks after the second dose of BNT162b2, the serum SARS-CoV-2-neutralizing activity was below the detection limit. It has been reported that only 44%-79% of patients with B-cell lymphoma produce sufficient antibodies after completing two doses of SARS-CoV-2 vaccines (Greenberger et al., 2021) . Rituximab is an anti-CD20 monoclonal antibody that significantly depletes B cells. In general, the rituximab-induced reduction of B cells persists no longer than 6 months after therapy completion (McLaughlin et al.,1998) . According to another report, rituximab also reduces functional T-cell response after vaccination (Nazi et al., 2013) . A cohort study in Japan reported that even beyond a year after the anti-CD-20 treatment, approximately 40% of the individuals had only acquired a limited amount of anti-SARS-CoV-2-IgG antibodies after two doses of BNT162b2 compared with healthy individuals (Okamoto et al., 2022) . Furthermore it is possible that delta variant mutations such as L452R can escape cell-mediated immunity, although SARS-CoV-2 mRNA vaccines generally generate a neutralizing response in 95% of recipients (Planas et al., 2021) , which may have influenced the lack of detectable SARS-CoV-2-neutralizing activity. These results imply that chemotherapies such as BR therapy critically compromise the immune system. Secondly, a high SARS-CoV-2 viral load was observed until 1 month after onset. Several reports have showed that patients with profound immunosuppression may shed viable SARS-CoV-2 for a prolonged period (Aydillo et al., 2020) although the details of the virological mechanism are not known. To the best of our knowledge, the mixed alleles found in this patient have not been reported to have any effect on immune escape. Further case series and virological studies are needed in this regard. Thirdly, elevated IFN-λ3 and IL-6, and severe lymphocytopenia as a manifestation of the tumultuous cytokine storm, were detected. These results suggest that a severe and uncontrolled cytokine storm resulted from the patient's immunologic unresponsiveness, which led to his death. Fourthly, while tocilizumab and steroids are effective in suppressing host inflammatory response phase, they can give rise to the risk of superinfection such as ventilator-associated bacterial pneumonia significantly (RECOVERY Collaborative Group, 2021. ) In this case, we could not deny the downside of these immunosuppressors even though we used adequately broad-spectrum antibiotics. COVID-19 treatment and prevention strategies for patients with hematologic diseases are not well established. The effectiveness of the mRNA vaccine in patients with hematologic malignancies seems restricted. Herishanu et al. (2021) reported that in 172 patients with chronic lymphocytic leukemia, the antibody response rate after the third BNT162b2 mRNA vaccine was only 23.8%. On the other hand, some articles indicate potential effectiveness of early deployment of convalescent plasma and monoclonal antibody therapies. Effectiveness of SARS-CoV-2 neutralizing antibodies following anti-CD20 therapies are still unclear as mentioned above, and further investigation is needed to set up the strategies for those vulnerable people. In conclusion, as the patients with hematologic malignancies are reasonably vulnerable to COVID-19 viral infection, further investigations are needed to establish prevention strategies. The guardian of this patient provided written informed consent to have his anonymized clinical information to be published. None. ☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Suboptimal response to COVID-19 mRNA vaccines in hematologic malignancies patients Shedding of viable SARS-CoV-2 after immunosuppressive therapy for cancer Successful treatment of prolonged COVID-19 with Bamlanivimab in a patient with severe B-Cell aplasia due to treatment with an anti-CD20 monoclonal antibody: A case report Successful Clearance of 300 Day SARS-CoV-2 Infection in a Subject with B-Cell Depletion Associated Prolonged (B-DEAP) COVID by REGEN-COV Anti-Spike Monoclonal Antibody Cocktail Bendamustine associated immune suppression and infections during therapy of hematological malignancies Asociación Madrileña de Hematología y Hemoterapia (AMHH). Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study Genomic epidemiology of hCoV-19, Global Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard two-dose vaccination Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19 Correlates of neutralizing/SARS-CoV-2-S1-binding antibody response with adverse effects and immune kinetics in BNT162b2-vaccinated individuals Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program The effect of rituximab on vaccine responses in patients with immune thrombocytopenia CD19-positive lymphocyte count is critical for acquisition of anti-SARS-CoV-2 IgG after vaccination in B-cell lymphoma Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Serum CCL17 level becomes a predictive marker to distinguish between mild/moderate and We thank all the medical staff and caregivers for their participation in the treatment. We also thank the guardians of this patient for approving this article to be published.